{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:03:53Z","timestamp":1784790233288,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"DOI":"10.7759\/cureus.113197","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:07:20Z","timestamp":1784786840000},"source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Sequencing (NGS) Utility in Advanced Solid Tumors in Low- and Middle-Income Country (LMIC) Setting"],"prefix":"10.7759","author":[{"given":"Prakriti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Manish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Badola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-anchem-062012-092628","article-title":"Next-generation sequencing platforms","volume":"6","author":"Mardis ER","year":"2013","unstructured":"Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif). 2013, 6:287-303. 10.1146\/annurev-anchem-062012-092628","journal-title":"Annu Rev Anal Chem (Palo Alto Calif)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele F","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, et al.. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020, 31:1491-1505. 10.1016\/j.annonc.2020.07.014","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton GM","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, et al.. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013, 31:1023-1031. 10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"29","author":"Mateo J","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, et al.. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT). Ann Oncol. 2018, 29:1895-1902. 10.1093\/annonc\/mdy263","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-1118","article-title":"Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors","volume":"5","author":"Dienstmann R","year":"2015","unstructured":"Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov. 2015, 5:118-123. 10.1158\/2159-8290.CD-14-1118","journal-title":"Cancer Discov"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.55","article-title":"Access to cancer medications in low- and middle-income countries","volume":"10","author":"de Lima Lopes G Jr","year":"2013","unstructured":"de Lima Lopes G Jr, de Souza JA, Barrios C. Access to cancer medications in low- and middle-income countries. Nat Rev Clin Oncol. 2013, 10:314-322. 10.1038\/nrclinonc.2013.55","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard C","year":"2017","unstructured":"Massard C, Michiels S, Fert\u00e9 C, et al.. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017, 7:586-595. 10.1158\/2159-8290.CD-16-1396","journal-title":"Cancer Discov"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071967","article-title":"Precision oncology: evolving clinical trials across tumor types","volume":"15","author":"Song IW","year":"2023","unstructured":"Song IW, Vo HH, Chen YS, Baysal MA, Kahle M, Johnson A, Tsimberidou AM. Precision oncology: evolving clinical trials across tumor types. Cancers (Basel). 2023, 15:1967. 10.3390\/cancers15071967","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2268","article-title":"Genomic medicine frontier in human solid tumors: prospects and challenges","volume":"31","author":"Dienstmann R","year":"2013","unstructured":"Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013, 31:1874-1884. 10.1200\/JCO.2012.45.2268","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle A","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al.. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020, 38:1-10. 10.1200\/JCO.19.02105","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus L","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, et al.. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021, 27:4685-4689. 10.1158\/1078-0432.CCR-21-0327","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0016-0","article-title":"The paradox of precision medicine","volume":"15","author":"Kimmelman J","year":"2018","unstructured":"Kimmelman J, Tannock I. The paradox of precision medicine. Nat Rev Clin Oncol. 2018, 15:341-342. 10.1038\/s41571-018-0016-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle M","year":"2015","unstructured":"Javle M, Churi C, Kang HC, et al.. HER2\/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015, 8:58. 10.1186\/s13045-015-0155-z","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458469-next-generation-sequencing-ngs-utility-in-advanced-solid-tumors-in-low--and-middle-income-country-lmic-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:07:21Z","timestamp":1784786841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458469-next-generation-sequencing-ngs-utility-in-advanced-solid-tumors-in-low--and-middle-income-country-lmic-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.113197","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}